CA2377422A1 - Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique - Google Patents

Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique Download PDF

Info

Publication number
CA2377422A1
CA2377422A1 CA002377422A CA2377422A CA2377422A1 CA 2377422 A1 CA2377422 A1 CA 2377422A1 CA 002377422 A CA002377422 A CA 002377422A CA 2377422 A CA2377422 A CA 2377422A CA 2377422 A1 CA2377422 A1 CA 2377422A1
Authority
CA
Canada
Prior art keywords
acid
lipid
periodic structures
disorder
pharmaceutically usable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377422A
Other languages
English (en)
Inventor
Gregor Cevc
Stefan Huebner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idea AG
Original Assignee
Idea AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idea AG filed Critical Idea AG
Publication of CA2377422A1 publication Critical patent/CA2377422A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
CA002377422A 1999-08-04 2000-08-03 Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique Abandoned CA2377422A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19936665.9 1999-08-04
DE19936665 1999-08-04
PCT/EP2000/007546 WO2001010413A2 (fr) 1999-08-04 2000-08-03 Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique

Publications (1)

Publication Number Publication Date
CA2377422A1 true CA2377422A1 (fr) 2001-02-15

Family

ID=7917131

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377422A Abandoned CA2377422A1 (fr) 1999-08-04 2000-08-03 Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique

Country Status (5)

Country Link
JP (1) JP2003506398A (fr)
AU (1) AU7271800A (fr)
CA (1) CA2377422A1 (fr)
PL (1) PL365423A1 (fr)
WO (1) WO2001010413A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
WO2002014548A1 (fr) * 2000-08-10 2002-02-21 Applied Gene Technologies, Inc. Compositions et procedes de traitement et d'amplification d'echantillons d'acides nucleiques
DE10132669B4 (de) * 2001-07-05 2008-08-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Pharmakologische Zubereitung aus einem nanopartikulären mesomorphen Polyelektrolyt-Lipid-Komplex und mindestens einem Wirkstoff
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2671447A1 (fr) 2006-12-01 2008-06-12 Anterios, Inc. Nanoparticules a entites amphiphiles
WO2008140594A2 (fr) 2006-12-01 2008-11-20 Anterios, Inc. Nanoparticules peptidiques et utilisations de celles-ci
WO2008151022A2 (fr) 2007-05-31 2008-12-11 Anterios, Inc. Nanoparticules d'acide nucléique et leurs utilisations
US20130022649A1 (en) * 2009-12-01 2013-01-24 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
KR101680834B1 (ko) * 2014-07-25 2016-12-01 연세대학교 산학협력단 알파 리포산을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
EP3541358A1 (fr) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Administration transdermique de grands agents
CA3163934A1 (fr) * 2019-11-08 2021-05-14 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Utilisation de lipide dans la preparation d'un reactif d'administration d'acide nucleique et produit associe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698721A (en) * 1992-12-17 1997-12-16 Megabios Corporation Catonic amphiphiles
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof

Also Published As

Publication number Publication date
AU7271800A (en) 2001-03-05
WO2001010413A3 (fr) 2001-08-16
WO2001010413A2 (fr) 2001-02-15
JP2003506398A (ja) 2003-02-18
PL365423A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
Maslov et al. Novel cholesterol spermine conjugates provide efficient cellular delivery of plasmid DNA and small interfering RNA
JP5480764B2 (ja) 両性リポソーム及びその使用
CA2377422A1 (fr) Structures periodiques comprenant des lipides, des polyelectrolytes, ainsi que des lieurs oligovalents solubles a induction de structure, et leur utilisation biologique
JP4175667B2 (ja) トランスフェクションのためのカチオン試薬
Harvie et al. Use of poly (ethylene glycol)–lipid conjugates to regulate the surface attributes and transfection activity of lipid–DNA particles
CA2335393C (fr) Complexes d'acides nucleiques encapsules dans des liposomes
Smith et al. Toward development of a non-viral gene therapeutic
US5705385A (en) Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP2002510615A (ja) 腹腔腫瘍に核酸を供給するカチオン性脂質製剤
US20200283795A1 (en) Plant virus movement proteins and methods of using same
JP2017523965A (ja) 脂質ナノ粒子ホスト中に核酸を封入する方法
KR20140101748A (ko) 지질-핵산입자를 멸균생성을 위한 단일 용도 시스템
Lepeltier et al. Self-assembly of squalene-based nucleolipids: relating the chemical structure of the bioconjugates to the architecture of the nanoparticles
KR20100085079A (ko) 핵산 유전자 전달용 저밀도 지단백질 유사(ＬＤＬ―ｌｉｋｅ) 양이온성 나노입자, 그의 제조방법 및 이를 이용한 핵산 유전자의 전달 방법
WO1991017424A1 (fr) Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
WO1998051285A2 (fr) Formulations amphiphiles cationiques
JPWO2006101201A1 (ja) 目的物質を効率的に核内に送達可能なリポソーム
Jääskeläinen et al. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides
Labas et al. Nature as a source of inspiration for cationic lipid synthesis
Eliaz et al. Interactions of hyaluronan-targeted liposomes with cultured cells: modeling of binding and endocytosis
WO1998045463A1 (fr) Composition pour l'introduction de genes dans des cellules
Fenske et al. Cationic poly (ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells
US20090010999A1 (en) Complex Particles and Coated Complex Particles
Koynova et al. Enhancing nucleic acid delivery, insights from the cationic phospholipid carriers
JPWO2006077857A1 (ja) 粒子を脂質膜で被覆する方法

Legal Events

Date Code Title Description
FZDE Dead